Table 6.
Aggregated findings per sequence and tumor type
| Modality | Tumor/Treatment | Studies | Patients | Effects | wsCoV |
|---|---|---|---|---|---|
| DSC | Brain/RTx | 4/5 | 123/142 | ↓ CBV 4.6–30% | 2.5–3.5% |
| Brain/BEV | ½ | 18/43 | ↓ CBF 20–30% | ||
| ASL | Breast/CTx | 3/3 | 82/82 | ↑ CBF 7–12% | 6.6–14.8% |
| Glioma III–IV/RCTx | 4/5 | 123/142 | ↓ CBF 10–23% | ||
| DCE | Brain/RCTx | 3/5 | 49/89 | ↑ Ve 8–12%, ↑ Ktrans 52% | 7.7% |
| Tc-99 m-HMPAO | Brain/RTx + SRS | 2/3 | 31/42 | ↓ CBF 4–22.5% | 15% |
| 1H-MRS | Breast/CTx | 4/4 | 79/79 | ↓NAA, NAA/Cr, or NAA/Cho 1–15% | 2.5–5.3% |
| Brain/RCTx | 12/13 | 244/284 | ↓ NAA/Cr 5–31%, NAA/Cho 15–19%, NAA 4–16%; ↑ Cho/Cr 4–20% | ||
| FDG-PET | NHL/CTx | ½ | 21/35 | ↓ FDG 20% | 10% |
| DKI | Non-CNS/RCTx | ¾ | 130/169 | ↓ MK 11–34% | 4–5.2% |
Tumor type: CNS central nervous system, NHL non-Hodgkin lymphoma
Treatment type: BEV bevacizumab, CTx chemotherapy, RTx radiotherapy, RCTx radiochemotherapy
Imaging: ASL arterial spin labeling, DKI diffusion kurtosis imaging, DSC dynamic susceptibility contrast, DCE dynamic contrast enhanced, FDG fluoro-deoxy-glucose, MRS magnetic resonance spectroscopy
Findings: CBF cerebral blood flow, CBV cerebral blood volume, Cho choline, Cr creatine, MK mean kurtosis, NAA N-acetyl aspartate, Ktrans extravascular and Ve extracellular fractional volume, wsCoV within-subject coefficient of variation
Summary results are given for each imaging technique and tumor type when the majority of studies that reported an observed parameter had results in concordance. Single studies, or studies where majority of findings were inconclusive or not in an agreement were not reported. The total number of studies and patients in concordance—out of the total number of studies and subject reporting comparable results—are given. Lastly, the within-subject across session coefficient of variation is provided to provide a reference of repeatability in healthy volunteers